Based on the Entera Bio Ltd stock forecast from 1 analysts, the average analyst target price for Entera Bio Ltd is USD 10.00 over the next 12 months. Entera Bio Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Entera Bio Ltd is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Entera Bio Ltd’s stock price was USD 1.69. Entera Bio Ltd’s stock price has changed by +5.62% over the past week, -8.65% over the past month and -43.29% over the last year.
No recent analyst target price found for Entera Bio Ltd
No recent average analyst rating found for Entera Bio Ltd
Company Overview Entera Bio Ltd
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The company leverage its N-Tab, an oral delivery technology, which is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. Its advanced product candidate is EB613 (oral PTH (1-34)) that is entering into Phase 3 development as the first oral, osteoanabolic (bone-building) once-daily tablet treatment for post-menopausal women with low bone mineral density and high-risk osteoporosis. The company is also developing EB612 as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism. In addition, it is developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and the first oral GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel. Read Less
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The company leverage its N-Tab, an oral delivery technology, whi...Read More
Frequently Asked Questions About Entera Bio Ltd (ENTX) Stock
Based on ratings from 1 analysts Entera Bio Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on ENTX's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for ENTX is USD 10.00 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 10.
Unfortunately we do not have enough data on ENTX's stock to indicate if its overvalued.
The last closing price of ENTX's stock was USD 1.69.
The most recent market capitalization for ENTX is USD 0.08B.
Based on targets from 1 analysts, the average taret price for ENTX is projected at USD 10.00 over the next 12 months.
This means that ENTX's stock price may go up by +491.72% over the next 12 months.
We can't find any ETFs which contains Entera Bio Ltd's stock.
As per our most recent records Entera Bio Ltd has 18 Employees.
Entera Bio Ltd's registered address is Kiryat Hadassah Minrav Building, Jerusalem, Israel, 9112002.
You can get more information about it from Entera Bio Ltd's website at https://www.enterabio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About Entera Bio Ltd (ENTX) Stock
Based on ratings from 1 analysts Entera Bio Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on ENTX's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for ENTX is USD 10.00 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 10.
Unfortunately we do not have enough data on ENTX's stock to indicate if its overvalued.
The last closing price of ENTX's stock was USD 1.69.
The most recent market capitalization for ENTX is USD 0.08B.
Based on targets from 1 analysts, the average taret price for ENTX is projected at USD 10.00 over the next 12 months.
This means that ENTX's stock price may go up by +491.72% over the next 12 months.
We can't find any ETFs which contains Entera Bio Ltd's stock.
As per our most recent records Entera Bio Ltd has 18 Employees.
Entera Bio Ltd's registered address is Kiryat Hadassah Minrav Building, Jerusalem, Israel, 9112002.
You can get more information about it from Entera Bio Ltd's website at https://www.enterabio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ENTX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
